Literature DB >> 4029888

Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA.

O Yokosuka, M Omata, F Imazeki, K Okuda, J Summers.   

Abstract

Twenty patients with HBeAg-positive chronic liver disease were given large doses of recombinant leukocyte interferon for 4 weeks. Changes of hepatitis B virus DNA in livers and sera were analyzed by the molecular hybridization technique in paired biopsies obtained before and 2 weeks after treatment. Serum hepatitis B virus DNA was examined before, during and after the treatment until 4 weeks post-interferon. Analysis of hepatic hepatitis B virus DNA revealed species that appeared to represent various forms of replicative hepatitis B virus DNA, i.e., relaxed circular, linear, supercoiled and single-stranded hepatitis B virus DNA, respectively. No evidence of integration of hepatitis B virus DNA in genomic DNA was obtained. Of 15 cases which were positive for hepatic hepatitis B virus DNA before treatment and in which paired biopsies were obtained, hepatic hepatitis B virus DNA became negative in 4, decreased in 5 and unchanged in 6. Among several types of replicative viral DNA in liver tissue, supercoiled hepatitis B virus DNA tended to remain after other forms were reduced. A close correlation between hepatic and serum hepatitis B virus DNA was found in 37 liver biopsy samples and corresponding sera. These results indicate that interferon treatment reduces serum hepatitis B virus levels by inhibiting viral replication in the liver and that persistence or reappearance of hepatitis B virus in serum after interferon is associated with replication.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029888     DOI: 10.1002/hep.1840050505

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

Review 1.  Update of research and management of hepatitis B.

Authors:  Takeshi Okanoue; Masahito Minami
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

Review 2.  The current status and future directions of hepatitis B antiviral drug discovery.

Authors:  Liudi Tang; Qiong Zhao; Shuo Wu; Junjun Cheng; Jinhong Chang; Ju-Tao Guo
Journal:  Expert Opin Drug Discov       Date:  2016-11-11       Impact factor: 6.098

3.  Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid.

Authors:  Y Wang; C Luscombe; S Bowden; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

4.  An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes.

Authors:  T Ochiya; T Tsurimoto; K Ueda; K Okubo; M Shiozawa; K Matsubara
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Authors:  S K Ono; N Kato; Y Shiratori; J Kato; T Goto; R F Schinazi; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

6.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Authors:  Yun-Fan Liaw; Nancy Leung; Jia-Horng Kao; Teerha Piratvisuth; Edward Gane; Kwang-Hyub Han; Richard Guan; George K K Lau; Stephen Locarnini
Journal:  Hepatol Int       Date:  2008-05-10       Impact factor: 6.047

7.  Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; D Colledge; Y Y Wang; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

8.  The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; Y Y Wang; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Effects of antiviral agents on chronic hepatitis B. Analysis using Cox proportional hazard model.

Authors:  S Takano; M Omata; O Yokosuka; F Imazeki; M Ohto
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

10.  Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha. Comparison with histological changes in chronic hepatitis B.

Authors:  M Omata; Y Ito; O Yokosuka; F Imazeki; K Uchiumi; S Takano; K Hosoda; M Ohto
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.